BRPI0820805A2 - Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina - Google Patents

Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina

Info

Publication number
BRPI0820805A2
BRPI0820805A2 BRPI0820805-0A BRPI0820805A BRPI0820805A2 BR PI0820805 A2 BRPI0820805 A2 BR PI0820805A2 BR PI0820805 A BRPI0820805 A BR PI0820805A BR PI0820805 A2 BRPI0820805 A2 BR PI0820805A2
Authority
BR
Brazil
Prior art keywords
oxepine
benzo
derived
receptor antagonist
mineralocorticoid receptor
Prior art date
Application number
BRPI0820805-0A
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820805(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0820805A2 publication Critical patent/BRPI0820805A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0820805-0A 2007-12-19 2008-12-09 Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina BRPI0820805A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0820805A2 true BRPI0820805A2 (pt) 2015-06-16

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820805-0A BRPI0820805A2 (pt) 2007-12-19 2008-12-09 Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina

Country Status (33)

Country Link
US (1) US7994164B2 (pt)
EP (2) EP2537845B1 (pt)
JP (1) JP5562866B2 (pt)
KR (1) KR101254382B1 (pt)
CN (1) CN101903377B (pt)
AR (1) AR069554A1 (pt)
AU (1) AU2008343524B2 (pt)
BR (1) BRPI0820805A2 (pt)
CA (1) CA2710409C (pt)
CL (1) CL2008003600A1 (pt)
CO (1) CO6300953A2 (pt)
DK (1) DK2235007T3 (pt)
DO (1) DOP2010000185A (pt)
EA (1) EA017668B1 (pt)
EC (2) ECSP10010266A (pt)
ES (2) ES2396605T3 (pt)
GT (1) GT201000179A (pt)
HR (1) HRP20120916T1 (pt)
IL (1) IL206353A (pt)
MA (1) MA31910B1 (pt)
MX (1) MX2010006911A (pt)
MY (1) MY150474A (pt)
NZ (1) NZ586300A (pt)
PE (1) PE20091057A1 (pt)
PL (1) PL2235007T3 (pt)
PT (1) PT2235007E (pt)
RS (1) RS52594B (pt)
SI (1) SI2235007T1 (pt)
TN (1) TN2010000292A1 (pt)
TW (1) TWI431010B (pt)
UA (1) UA100131C2 (pt)
WO (1) WO2009085584A1 (pt)
ZA (1) ZA201004257B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018657A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
WO2010104721A1 (en) * 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
EP2568986B1 (en) 2010-05-10 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
MD20150103A2 (ro) 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
ME03316B (me) 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora
JP2017531684A (ja) * 2014-11-21 2017-10-26 イーライ リリー アンド カンパニー 腎障害の治療のための１，２−ベンゾチアゾール化合物
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
WO2018054357A1 (zh) * 2016-09-24 2018-03-29 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途
EP4118235B1 (en) 2020-03-11 2026-08-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
CN117510398A (zh) * 2023-11-02 2024-02-06 上海诺丁太生物科技有限公司 一种高光学纯度(3r,4r)/(3s,4s)-n-boc-4-氨基-3-羟基哌啶的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) * 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
ES2260497T7 (es) * 2001-11-21 2009-11-05 Millennium Pharmaceuticals, Inc. Antagonistas de receptores de quimioquininas y metodos de uso de los mismos.
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
DE602004014640D1 (de) * 2003-12-19 2008-08-07 Lilly Co Eli Tricyclische modulatoren von nuklearen steroidhormonrezeptoren
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
RU2007107177A (ru) * 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
SG161261A1 (en) 2004-11-10 2010-05-27 Incyte Corp Lactam compounds and their use as pharmaceuticals
ES2375877T3 (es) 2006-10-31 2012-03-07 Pfizer Products Inc. Compuestos de pirazolina como antagonistas de receptores de mineralocorticoides.
JP2010522732A (ja) 2007-03-29 2010-07-08 ナームローゼ・フエンノートチヤツプ・オルガノン 鉱質コルチコイド受容体アンタゴニスト
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009094157A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
MA31910B1 (fr) 2010-12-01
PT2235007E (pt) 2013-01-22
HRP20120916T1 (hr) 2012-12-31
AR069554A1 (es) 2010-02-03
EP2537845A1 (en) 2012-12-26
EA201070762A1 (ru) 2010-12-30
ES2459318T3 (es) 2014-05-09
UA100131C2 (uk) 2012-11-26
MY150474A (en) 2014-01-30
AU2008343524B2 (en) 2012-03-08
DOP2010000185A (es) 2010-09-15
PE20091057A1 (es) 2009-07-20
ZA201004257B (en) 2011-11-30
PL2235007T3 (pl) 2013-03-29
TN2010000292A1 (en) 2011-11-11
CN101903377A (zh) 2010-12-01
NZ586300A (en) 2012-06-29
CN101903377B (zh) 2014-07-09
JP2011507868A (ja) 2011-03-10
EP2235007B1 (en) 2012-10-31
HK1144284A1 (en) 2011-02-11
CA2710409C (en) 2012-11-06
KR101254382B1 (ko) 2013-04-15
CO6300953A2 (es) 2011-07-21
TWI431010B (zh) 2014-03-21
ECSP12012048A (es) 2012-08-31
RS52594B (sr) 2013-04-30
EA017668B1 (ru) 2013-02-28
ECSP10010266A (es) 2010-07-30
GT201000179A (es) 2012-04-16
CL2008003600A1 (es) 2010-02-19
KR20100082866A (ko) 2010-07-20
ES2396605T3 (es) 2013-02-22
SI2235007T1 (sl) 2013-01-31
EP2537845B1 (en) 2014-03-19
US7994164B2 (en) 2011-08-09
TW200930721A (en) 2009-07-16
WO2009085584A1 (en) 2009-07-09
IL206353A0 (en) 2010-12-30
CA2710409A1 (en) 2009-07-09
US20090163472A1 (en) 2009-06-25
EP2235007A1 (en) 2010-10-06
IL206353A (en) 2014-06-30
DK2235007T3 (da) 2012-12-17
MX2010006911A (es) 2010-10-05
AU2008343524A1 (en) 2009-07-09
JP5562866B2 (ja) 2014-07-30

Similar Documents

Publication Publication Date Title
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
BRPI0820447A2 (pt) Agonistas do receptor de glicocorticóides
BRPI0821784A2 (pt) receptor de navegação
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
BRPI0911563A2 (pt) uso de antagonista da progesterona
BRPI0810926A2 (pt) Antagonista de crig
EP2350060A4 (en) Melanocortin receptor AGONISTS
EP1981902A4 (en) NOGO RECEPTOR ANTAGONISTS
EP2163693A4 (en) CONSTRUCTION MACHINE
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
EP2362779A4 (en) CXCR4 RECEPTOR COMPOUNDS
BRPI0907382A2 (pt) Antagonista de receptor de opioide seletivo capa.
BRPI0810613A2 (pt) derivados de tetra-hidrocarbazol como ligantes de receptores acoplados à proteína g
DK2081951T3 (da) Progesteron-receptorantagonister
BRPI0812155A2 (pt) derivados de espiroindolinona
PL2235007T3 (pl) Niesteroidowi antagoniści receptora mineralokortykoidowego pochodzący od 6H-dibenzo[B,E]oksepiny
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
EP2206502A4 (en) POLYMER CONJUGATE OF A STEROIDS
BRPI0815246A2 (pt) Composição de catalisador

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]